Search clinical trials for: amibegron (SR58611A)

Total 28 results

Sanofi

Completed

Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder

Major Depressive Disorders

Russian Federation, Spain, Singapore, Taiwan, Tunisia, Argentina, Chile, Hong Kong, Morocco, South Africa, Greece
Sanofi

Completed

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)

Major Depressive Disorder

United States
Sanofi

Completed

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression (ZEPHIR)

Depressive Disorder

Romania, Bulgaria, Serbia, Slovakia, Finland
Sanofi

Completed

Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder (LIBRA)

Anxiety Disorder

United States
Sanofi

Terminated

Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder (VEGA)

Anxiety Disorders

France, Russian Federation, Australia, Germany, Spain, Mexico, Hungary, Italy, Chile
Sanofi

Completed

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (PHOENIX)

Major Depressive Disorder

United States, Canada
Sanofi

Completed

A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder (CALYPSO)

Depressive Disorder | Major Depression

France, Poland, Romania, Russian Federation, Bulgaria, Serbia, Slovakia, Czech Republic, Mexico, Argentina, Croatia, Finland, South Africa
Sanofi

Completed

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (ORION)

Major Depressive Disorder

United States, Canada
Sanofi

Terminated

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder (GEMINI)

Anxiety Disorders

Romania, Slovakia, Croatia, Austria, Finland
Sanofi

Completed

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder (AQUARIUS)

Anxiety Disorders

France, Russian Federation, Sweden, Estonia, Argentina, Austria, South Africa
Sanofi

Completed

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder (ELECTRA)

Anxiety Disorders

Poland, Bulgaria, Serbia, Czech Republic, Croatia
Sanofi

Completed

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

Major Depressive Disorders

United States
Sanofi

Completed

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Major Depressive Disorders

France, Netherlands, Bulgaria, Estonia, Serbia, Czech Republic, Croatia, Montenegro
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Germany, Japan
Sanofi

Completed

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder (ALBERIO)

Major Depressive Disorder

France, Germany, Turkey, India, Malaysia, Taiwan, Belgium, Tunisia, Finland, Korea, Republic of, Morocco, Greece, Estonia
Urovant Sciences GmbH

Recruiting

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC (KANGUROO)

Neurogenic Detrusor Overactivity

United States
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

Overactive Bladder
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

Overactive Bladder
Urovant Sciences GmbH

Active, not recruiting

Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)

Overactive Bladder

United States
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Overactive Bladder

United States, Spain, Canada, Portugal, Poland, Belgium, Hungary, Lithuania
Urovant Sciences GmbH

Completed

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Overactive Bladder

United States, Poland
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Urovant Sciences GmbH

Completed

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)

Overactive Bladder

United States, Latvia, Hungary, Canada, Lithuania, Poland
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Urinary Bladder, Overactive
Janssen Research & Development, LLC

Completed

A Study in a Human Laboratory Model of Smoking Behavior

Smoking

United States
Merck Sharp & Dohme LLC

Terminated

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Overactive Bladder | Overactive Urinary Bladder
Urovant Sciences GmbH

Completed

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (Empowur)

Overactive Bladder

United States
Women and Infants Hospital of Rhode Island
Patient-Centered Outcomes Research Institute; University of California, San... and other collaborators

Recruiting

Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence (BEST)

Urgency Urinary Incontinence

United States

3

Subscribe